Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of central nervous system disorders. The company's lead product, NUPLAZID (pimavanserin), is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Acadia is also developing a number of other potential therapies for the treatment of Alzheimer's disease, schizophrenia, and other CNS disorders.